Virtual Library

Start Your Search

Y.X. Shen



Author of

  • +

    P1.07 - Poster Session/ Small Cell Lung Cancer (ID 221)

    • Event: WCLC 2015
    • Type: Poster
    • Track: Small Cell Lung Cancer
    • Presentations: 1
    • +

      P1.07-012 - Hypo- or Conventionally Fractionated Radiotherapy in Patients with Limited Stage Small Cell Lung Cancer (LS-SCLC): A Retrospective Analysis (ID 2565)

      09:30 - 17:00  |  Author(s): Y.X. Shen

      • Abstract
      • Slides

      Background:
      Previous data from our institution showed that hypofractionated thoracic radiotherapy (HypoTRT) concurrently with etoposide/platinum chemotherapy yielded favorable survival in patients with LS-SCLC. The aim of the present study was to compare the survival outcomes, failure patterns and toxicities between groups of LS-SCLC patients treated with conventionally fractionated radiotherapy (ConvTRT) or HypoTRT combined with etoposide/platinum chemotherapy.

      Methods:
      Medical records of LS-SCLC patients between January 2010 and December 2013 at Fudan University Shanghai Cancer Center were retrospectively reviewed. All patients treated with chemotherapy and ConvTRT (2.0 Gy per faction daily, DT≥56Gy) or HypoTRT (2.5 Gy per faction daily, DT= 55Gy) were eligible for analysis. The progression-free survival (PFS) and overall survival (OS) were generated for different populations using the Kaplan-Meier method and compared by log-rank test. The comparison of failure patterns and toxicity were analyzed with the χ[2] test.

      Results:
      One hundred and seventy-nine patients were indentified. All patients received 1-6 cycles of Etoposide/Platinum chemotherapy. Except for nine patients who received hyperfractionated regimen, 170 of 179 patients treated with were eligible for analysis (median age 58 years; male 85.3%). Sixty-nine patients received HypoTRT and 101 patients received ConvTRT (median 60Gy/30Fx). PCI (25Gy/10Fx) was given to patients with partial or complete remission in chest tumor. PCI was administered to 46 (66.7%) and 48 (47.5%) patients in HypoTRT and ConvTRT cohorts (p=0.014), respectively. Except for PCI, the patient- or treatment-related variables were similar between the two cohorts. With a median follow-up of 23 months, the median OS was 26.7 months (95%CI: 23.2-30.2) in the ConvTRT cohort and 30.4 months (95%CI: 25.6-35.2) in the HypoTRT cohort (p=0.221). The 2-year OS for the ConvTRT and the HypoTRT cohort were 56.0% and 62.8%, respectively. The median PFS was 19.3 months for patients received HypoTRT, which was similar to that of the ConvTRT group (13.7 months, p=0.375). Sixty-three patients(62.4%) experienced disease progression in ConvTRT cohort, compared with 41 patients(59.4%) in HypoTRT cohort. The patterns of failure (stratified by local-regional recurrence, distant metastasis or both as first relapse) were also similar between the two dose cohorts (p=0.219, p=0.466, p=0.724). The 2-year local-regional progression free survival rates for the ConvTRT and HypoTRT cohorts were 59.7% and 70.6% (p=0.128), respectively. PCI reduced the incidence of brain metastasis by 31% at 20 months. Patients who received PCI had a significant longer survival with a 2-year OS rate of 69.8%, as comparing 44.4% of those who did not (p=0.000). Concurrent chemoradiotherapy was another predictor for favorable survival. However, patients who were treated with concurrent approach tended to be younger, receive early thoracic radiotherapy, more cycles of chemotherapy and PCI. No differences in treatment-related toxicity rates were demonstrated between the two dose-prescription cohorts (p=0.815). Grade ≥3 esophagitis and pneumonitis occurred in 9.9% and 9.9% in ConvTRT cohort, whereas 11.6% and 8.6% in HypoTRT cohort, respectively.

      Conclusion:
      In this retrospective analysis, HypoTRT or ConvTRT combined with etoposide/platinum chemotherapy yielded statistically similar survival, treatment failure outcomes, and toxicity profiles.

      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.